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Summary.-Eleven groups of workers submitted a total of 21 bronchial tumour-
associated antigen preparations and 19 antisera for comparative studies. Many of
the antisera proved to be polyspecific despite absorption procedures. Most of the
antigen preparations contained some material reactive towards a reference antiserum
to normal human serum proteins.
While it appeared that no participants were studying identical antigen-antibody
reactions, several cross-reactivities were identified in the antisera. When immune
reactions to CEA, AFP, NCA, ferritin, lactoferrin, human pepsin and gastricsin, and
the pregnancy proteins, SP1 and SP3 were excluded by use of reference antisera and
electroimmunoprecipitation methods, there remained 5 antigen-antibody reactions
defining unique antigens. The clinical usefulness of any of these 5 antigens has yet to
be determined.
VARIOUS groups of workers have re-
ported attempts to identify antigenic
markers for bronchial cancer. The possi-
bility arose that different groups might
not be aware that they were studying
similar substances. Also, it was possible
that some groups might have found more
promising leads in this field which others
would wish to follow. Under the auspices
of the International Agency for Cancer
Research, groups known to be working in
this field (see Table I) were invited to
submit antigens and antisera for compara-
tive studies, the preliminary results of
which were then presented at a workshop
held at Charing Cross Hospital, London,
on 7 September 1979.
The specific objectives were to deter-
mine any cross-reactivities that might
exist between different antigen prepara-
tions when precipitated with (a) antisera
provided by the participants to their own
antigens, and (b) antisera raised to known
proteins, e.g. CEA. The possible presence
of antibodies to normal human serum pro-
33
teins in the antisera was also investi-
gated.
MATERIALS AND METHODS
Antigen samples.-The 21 antigen samples
submitted for the study are listed in Table II,
which indicates that these extracts were
made from bronchial tumours of different
histological types, or their associated effusion,
or from tumour cell lines; the methods of
extraction can also be seen to be diverse.
The samples were stored at - 20°C and
thawed and kept at 4°C during use, before
re-freezing.
Antisera.-The 19 antisera submitted by
the participants are listed in Table III (Nos
1-19). These were raised to extracts as
described in Bell & Seetharam (1976), Gaffar
et al. (1979), Gennings et al. (1979, Gropp et al.
(1979), Ibrahim et al. (1980), Lamerz et al.
(1979), McIntire & Sizaret (1974), Mohr et al.
(1974), Veltri et al. (1977, 1980), Wolf (1978).
In the case of Ford et al. (1980), the antisera
were raised to viable bronchial tumour cells in
culture. It may be noted that there are wide
differences in the normal tissues with whichJ. N. GENNINGS, K. D. BAGSHAWE, N. H. AXELSEN AND P. SIZARET
TABLE I.-Participants in bronchial tumour-associated antigens study
Address
C. H. Ford
C. E. Bell
C. Gropp
A. Wolf
R. W. Veltri
K. R. McIntire
A. N. Ibrahim
S. Ikeda
R. Lamerz
J. N. Gennings
R. E. Nordquist
Surgical Immunology Unit, Department of Surgery, Queen Elizabeth Hospital,
Birmingham, U.K.
Division of Laboratory Medicine, Department of Pathology and Medicine,
Washington University School of Medicine, Saint Louis, Missouri, U.S.A.
Medizinische Universitatsklinik, Marburg, Federal Republic of Germany.
Institute for Cancer Research, University of Vienna, Vienna, Austria.
Division of Otolaryngology, West Virginia University Medical Center, Morgantown,
West Virginia, U.S.A.
Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland, U.S.A.
Department of Biology, Georgia State University, Atlanta, Georgia, U.S.A.
Respiratory Division, Kyoto-Katsura Hospital, Nishikyo, Kyoto, Japan.
Med. Klinik II, Klinikum Grosshadern, Universitat Munchen, Munchen, Federal
Republic of Germany.
Department of Medical Oncology, Charing Cross Hospital, London, U.K.
Department of Medicine, Health Sciences Center, University of Oklahoma,
Oklahoma City, Oklahoma, U.S.A.
TABLE II.-Antigen samples submittedfor the study
Antigen
No.
1
2
3
8
4
6
5
7
9
10
11
12
Group
Gropp
Wolf
Veltri
McIntire
Ibrahim
Ikeda
13
Antigen name
MR
WG
S
TMTE
TAMA.1
TAMA.2
(Normal)
(Normal)
(Normal)
LT
#25
#28
TS.1
TS.2
14, 15 Lamerz LCEAS/l
LCAA-1
LCAA-2
16, 17 LCEP
LCAA-3
LCAA-4
18 Lamerz LCEAS/III
LCAA-1 and -4
19 LCEAS 6B/II
LCAA-1 and -2
20 Gennings J14-LTA
21 Nordquist
Histological type
Squamous cell
Squamous cell
Squamous cell
Squamous cell
Epidermoid
squamous cell
Squamous cell
Adenocarcinoma
Mixed: adeno-,
squamous cell
and large cell
carcinoma
Squamous cell
Squamous cell
Squamous cell
Squamous cell
All major types
Alveolar cell
membrane
Notes
Glycoprotein
Extract of pleural effusions
Chromatographed on DEAE
Purified by binding to wheat germ lectin
and Concanavalin A
Probably glycoprotein
As for WG antigen, but further purified
Probably glye3protein
Triton X-100 extracts of cell membrane
Separated on DEAE-cellulose:
(I) unbound fraction
(II) bound fraction
Corresponding fraction to TAMA.1
from normal tissue
Corresponding fraction to TAMA.2
from normal tissue
Extracted in saline
Glycoprotein
KCI extract
Further purified form of#25
Lung metastases from gastric primary
tumour
Extracted in distilled water
Glycoprotein
Known to be CEA-like
Extracted in distilled water
Glycoprotein
Saline/KCl/ammonium sulphate extract
Known to be ferritin-like
Known to be lactoferrin-like
Saline/perchloric acid extract
Known to be CEA-like
Known to be NCA-like
Saline/KCl/ammonium sulphate extract
Saline/KCl/ammonium sulphate extract
Saline extract
Probably glycoprotein
Membrane proteins extract
Group
1
2
.1
4
5
6
7
8
9
10
11
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these antisera were absorbed. In addition to
these 19 antisera provided by the participants
10 other antisera (Nos 20-29 in Table III)
raised to known proteins were also studied.
Antisera Nos 1-19 were stored at -200C
and Nos 20-29 at 4°C.
Eight groups were able to provide both
antigen and antiserum samples; 2 groups
provided antisera only and 1 group antigen
only.
The antigen-antibody reactions were in-
vestigated first by immunodiffusion and then
by electroimmunoprecipitation, after some
preliminary ranking, according to cross-
reactivity between the different systems, had
been established. The initial immunodiffusion
results served mainly to demonstrate the
complexity ofthe problem of comparison. No
evidence obtained from the preliminary
immunodiffusion studies conflicted with the
conclusions drawn from fused rocket im-
munoelectrophoresis which are presented
here.
Electroimmunoprecipitation.-Two methods
of electrophoretic separation were used:
(1) Fused-rocket immunoelectrophoresis
(IEP), (2) crossed IEP with intermediate gel.
The methods are described in Axelsen et al.
(1973).
Glass plates (10 x 10 cm, 7 x 10 cm or
5 x 7 cm) were spread to a thickness of 1-5
mm with agarose (type HSA; electroendos-
mosis Mr= -0413; Litex, Glostrup, Den-
mark). Tris-Barbital buffer was used in the
electrophoresis (pH 8-6; ionic strength 0 02).
Sections ofgel to which antibody was added
generally contained between 1-7 and 3.3%
antiserum.
The antigen wells punched in the gel were
filled with 5 ,u antigen solution. Concentra-
tions used were those recommended by each
participant to ensure precipitation.
The majority ofthe fused rocket plates had
21 holes punched along one side containing
the 21 antigen samples. Each plate had pre-
sent in the gel one of the antisera under
investigation.
First-dimension electrophoresis in crossed
IEP was carried out at 10 V/cm until a
bromophenol-stained albumin marker had
migrated a suitable distance, and second-
dimension electrophoresis (and fused-rocket
IEP) at 2 V/cm overnight. After electro-
phoresis the plates were pressed, washed for
10 min in 01M NaCl, pressed, dried and
stained with Coomassie brilliant blue R.
RESULTS
All 21 antigens were screened by fused-
rocket IEP against all antisera (19 pro-
vided by participants and 10 raised to
known proteins, as listed in Table III).
The precipitates which were formed
between the antisera and antigens in these
fused-rocket experiments were noted; in
some cases more than one precipitate was
formed by the reaction of one antigen
sample with one antiserum.
The probability of two antisera being
identical (same specificities and titres) is
very high if two fused-rocket plates, pro-
duced by two different antisera look
identical when a large panel of antigen
sample is compared.
An example of antisera with common
specificities is evident when Figs 1 and 2
are compared.
In Fig. 1 the gel contains anti-ferritin
(a-ferritin; antiserum 24; ab 24) and
characteristic heavy-staining peaks are
produced by antigen (ag) nos 1, (6), 8, 9,
10, 12, 13, 15, 18 and 19: these are seen to
be reproduced in Fig. 2 where ab 16
(Lamerz 12/13, absorbed) is present in the
gel; the peaks in the two Figures are pro-
portional in size to each other and are of
the same morphology. From this it may
be concluded that ab 16 contains a-
ferritin-like antibodies, although other
antibody types are additionally present,
as indicated by the additional peaks of
different morphological type produced by
ag 1, 8, 9, 10 and 17.
By defining the antisera with which an
antigen sample forms a precipitate, its
components can be "finger-printed", and
these are summarized for each antigen in
Table IV.
Different types of precipitates were
often discernible. For example, in Fig. 3,
where ab 15 (Ikeda a-TS,2 absorbed) is
present in the gel, ag 11, 12 and 13 form
a pointed, fuzzy precipitate which differs
from the pointed but distinct peak pro-
duced by ag 2; of different morphology
again is the rounded precipitate formed by
ag 11, 12, 13, 15 and 16, while afourthtype
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TABLE III.-Antisera investigated in the study
Group
Ford
Ford
Ford
Ford
Ford
Ford
Bell
Bell
Antiserum name
6 IV abs
6 IV unabs
21 IV abs
21 IV unabs
351 abs
408 abs
MI da 1247 abs
M14 da 274 abs
Species Immunization material
Goat Cultured oat-cell carcinoma
cells
Monkey Oat-cell plasma membranes
Monkey Epidermoid plasma
membranes
Goat MR antigen
Rabbit KFV:Ag (S) antigen
Absorption material
Spleen ( x 3)
Spleen ( x 3)
Spleen ( x 2)
Spleen ( x 2)
NHS
NHS
Pool of NHLu
NHP
erythrocytes, thrombo-
cytes, bacteria, fungi
and foetal extracts
Pleural effusion (non-
malignant), NHLu
NHS, NHLu, pool of
Triton X.100 extracted
normal lungs
Insolubilized NHP,
NHLu, pooled A, B,
0 erythrocytes
Pooled NHLu, NHS
and NHP
NHLu
NHLu
NHS
A, B and 0 erythrocytes
NHLu and NHS
NHS
A, B and 0 erythrocytes
NHS, NHLu and NHLi
9 Gropp MR.1. anti
10 Wolf KFV:ASP (a)
11 Veltri Anti-LTAA-1 Rabbit Antigen LTAA.1
(=_TAMA.1)
12 McIntire R 201A Rabbit
13 Ibrahim Anti-Lu Ca TAA Rabbit
14 Ikeda Anti-TS.1 Rabbit
(y-globulin fraction
provided)
15 Ikeda Anti-TS.2 Rabbit
(y-globulin fraction
provided)
16 Lamerz 12/13 Rabbit
17 Lamerz Peter Rabbit
18 Lamerz 24 Rabbit
19 Gennings J 14 Rabbit
Additional antisera investigated:
Antiserum
No. Specification
20 anti-human serum prot
21 anti-AFP
22 anti-CEA
23 anti-NCA
Pooled extracts of
epidermoid squamous
cell lung ca.
LuCa TAA antigen
(crude extract)
TS.1 antigen
TS-2 antigen
LCEAS G 200/I (LCAA-1
and -2 antigens)
LCEAS G 200/I (LCAA-1
and -2 antigens)
LCEP (LCAA-3 and -4
antigens)
J8-LTA antigen
tein
24 anti-ferritin
25
26
27
28
anti-lactoferrin
anti-SP.1
anti-SP.3
anti-human pepsin (abs)
Source
Dako, Copenhagen, Denmark
Dako
Dako
C. S. Nielsen, Protein Lab., Univ. of
Copenhagen, Denmark
Dako
Behring, Frankfurt (Maine), W. Germany
Dako
Dako
N. H. Axelsen, Statens Seruminstitut,
Copenhagen
29 anti-human gastricsin N. H. Axelsen
Abbreviations used in this table: NHS = normal human serum; NHP = normal human plasma; NHLu =
normal human lung; NHLi =normal human liver; abs =absorbed; unabs =unabsorbed.
Anti-
serum
No.
1
2
3
4
5
6
7
8
490491 STUDY ON BRONCHIAL ANTIGENS
20 18 16 13 11 9 7 5 3 1
21 19 17 15 12 10 8 6 4 2
FiG. 3.-Fused-rocket IEP. Gel contains ab
15, Ikeda anti-TS.2 absorbed antiserum
(3-3% v/v). Wells as in Fig. 1.
21 19 17 15 12 10 8 6 4 2
FIG. I.-Fused-rocket IEP. Gel contains ab
24, anti-ferritin (Dako; 3-3% v/v). Num-
bers refer to wells containing antigen
samples (code in Table II).
20 18 16 13 11 9 7 5 3 1
20 18 16 13'i1 9 '7 5 3 1
21 19 17 15 12 10 8 6 4 2
21 19 17 15 12 10 8 6 4 2
FIG. 4.-Fused-rocket IEP. Gel contains ab
22, anti-CEA antiserum (Dako; 3-3% v/v).
Wells as in Fig. 1.
Five of the participants' antisera (ab 2,
Ford 6 IV unabsorbed; ab 4, Ford 21 IV
unabsorbed; ab 14, Ikedaii-TS.I absorbed;
ab 15, Ikeda ii-TS.2unabsorbed and ab 18,
Lamerz "24" absorbed) demonstrated
anti-CEA-like activity (as well as other
activities). For example, it appears likely
that the precipitates produced by ag I1,
12 and 13 in Figs 3 and 4 are due to the
reaction of CEA with anti-CEA.
Fw. 2.-Fused-rocket IEP. Gel contains ab
16, Lamerz 12/13 absorbed antiserum
(3-3% v/v). Wells as in Fig. 1.
is seen in the small precipitate produced
by ag 9, 12 and 13.
CEA-likeactivity
As indicated in Table 1V, several of the
antigens demonstrated CEA-like activity.
This is apparent in Fig. 4, where ab 22
(&-CEA) is present in the gel.J. N. GENNINGS, K. D. BAGSHAWE, N. H. AXELSEN AND P. SIZARET
TABLE IV.-Distribution of "identified" antigens in the antigen samples
Antigen sample number
I
Antigen name 1 2 3
Gropp (MR)
Wolf ("A") + +
Wolf ("WG") +
Ibrahim
Ikeda ("TS.2")
Lamprz (LCAA.1 & 2) +
Lambrz (LCAA.3 & 4)
Gennings (J14.LTA)
Nordquist
Human serumproteins + + +
CEA
NCA
Ferritin +
Lactoferrin
Human pepsin +
, 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
+ + +
+ +
+ + + +
++ ++ + ++ + + + + +
+ +
+
+ +
+ (+) +
+
+ + + + + +
+ + + + + + + +
+ + + ++ +++ + +
+ + + +++++ + +
+~~~~~~~ ++
+ ++++++
The anti-CEA activity of 4 of these
antisera (ab 2, 4, 14 and 15) was confirmed
by carrying out fused-rocket IEP of the
antigens with CEA-like activity into an
intermediate gel containing either ab 2, 4
or 15 and then into gel containing ab 22
(a-CEA). The intermediate gel was seen
to absorb the CEA-like activity of the
antigens in some cases, so that there was
no migration into the anti-CEA-containing
gel and no precipitation there.
It was therefore demonstrated beyond
reasonable doubt that antigen nos 8, 11,
12, 13, 15, 16, 17 and 18 contained CEA-
like activity and that antisera nos 2, 4, 14,
15 and 18 reacted with these in the same
way as anti-CEA (Dako) indicating their
similar anti-CEA-like qualities. In the
same way other components ofthe antigen
samples can be identified by their reaction
with others of the panel of antisera used.
Table IV, where the "known" antigenic
constituents of the antigen samples are
summarized, indicates that the antigen
samples discussed above which contain
CEA-like material also have other com-
ponents.
Table IV also indicates the occurrence
of known proteins, e.g. CEA and ferritin,
in the antigen samples. It will be noticed
that all samples contain some human
serum proteins; this would in fact be
expectedin most ofthese preparations (see
methods of extraction in Table II). In
many cases the amount present would be
undetectable by simple immunodiffusion,
but traces were demonstrable by. the
higher sensitivity of fused-rocket IEP.
Human serumproteins
In another set of experiments using
crossed IEP, antisera were investigated
for the presence of antibodies to human
serum proteins.
In fact only one antiserum (ab 10, Wolf)
was judged to contain such an antibody,
which was identified as anti-x2-macro-
globulin; this finding was of use in inter-
preting the fused-rocket IEP plate, where
ab 10 was present in the gel. Certain pre-
cipitates of a distinct morphological type
produced by certain of the antigens could
thus be identified as aX2-macroglobulin,
while morphologically different rockets
may be attributed to other antigen-anti-
body systems.
This type of screening for known pro-
teins is very useful in estimating "known"
proteinsfrom aheterogeneouspreparation.
Apparently distinct antigen-antibody
reactions
Table V presents a summary ofthe con-
tent ofantibody specificities in the partici-
pants' antisera. As would be expected
when antisera have been raised against
only partially purified preparations, anti-
bodies are in some cases present not only
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TABLE V.-Summary ofprobable content ofantibodyspecificities intheinvestigated antisera
Antiserum
No. Reactivity
Ab 1 Mono
Ab 2 Poly
Ab 3 Mono
Ab 4 Poly
Ab 5 Inactive
Ab 6 Inactive
Ab 7 Mono
Ab 8
3 Gropp Ab 9
4 Wolf Ab 10
5 Veltri
Mono
Mono
Poly
Notes
+ barely detectable undefined
reaction against Ag No. 18
i "a-CEA"
ii "al-Nordquist"
iii "al-Gennings"
iv +2 other undefinable reactivities
+ very weak reaction with Ag 18
"a-Nordquist"
+ very weak reaction with Ag 18
i "fa-CEA"
ii "a-Nordquist"
iii "a-Gennings"
iv + very weak reaction with Ag 18
possible slight reaction with Ag 18
possible slight reaction with Ag 18
Immunodiffusion studies indicated
reactivity with Ag 18 (not
confirmed by IEP)
As for Ab 7
al-MR.l (Gropp)
At least two different reactivities:
i High mobility peaks are produced
by antimacroglobulin
ii Low mobility peaks at least one
other undefinable species of
antibody "f-Wolf A"
Ab 11 Mono Immunodiffusion studies indicated
rea ctivity with Ag Nos 8 (Veltri),
12 and 13 (Ikeda), (not confirmed
by IEP
6 McIntire Ab 12 Inactive
7 Ibrahim Ab 13 Poly Two reactivities apparent:
i undefined
ii "a-Ibrahim" (unique)
8 Ikeda Ab 14 Poly i "f-Wolf ag WG"
("Wolf ag WG" is not CEA, or
any serum protein; it is present
in ag 2, but is not similar to any
other antigens)
ii "al-CEA"
Ab 15 Poly i "f-Wolf ag-WG"
ii "a-CEA"
iii "fa-TS.2"
9 Lamerz Ab 16 Poly i f-ferritin
ii f-lactoferrin
iii at least 2 more undefined
reactivities (not a-serum proteins)
Ab 17 Poly i fl-ferritin
ii at least one other antibody of
undefined reactivity-similar to
one of those in ab 16)
Ab 18 Poly i f-CEA
ii fl-NCA
iii at least one other antibody of
undefined reactivity
10 Gennings Ab 19 Mono "-aGennings"
Group
1 Ford
2 Bell
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TABLE VI.-Conclustons concerning iden-
tity/non-identity between NAMED anti-
gens and antigens notdemonstrated in this
study
1 "Gropp antigen" (MR) was not demonstrable in
sample submitted as such, but precipitates were
formed by ag 8, 9, 10 and 19 with Gropp anti-
serum (MR-1. anti).
2 "Wolf antigen A" was found only in ag 2 and 3
(Wolf) and ag 15 and 17 (Lamerz). Although
this antigen appears to be similar to ag 12
("Ikeda ag TS.1"), it nevertheless does not
precipitate with a-CEA (Dako); further, radio-
immunoassay for CEA (Hoffman-Laroche,
Vienna) similarly indicates that "Wolf antigen
A" contains no CEA determinants identified by
this assay.
3 A unique antigen, "Wolfantigen WG" occurs in
ag 2 in addition to "Wolf antigen A" which
occurs in both ag 2 and 3. "Wolf antigen WG"
is recognized by ab 14 and 15.
4 Veltri antigens (TAMA-1 and -2) were not
demonstrable. However, in these experiments
precipitin lines were allowed to develop for
18 h. Dr Veltri points out that in order to
demonstrate TAMA-1 he finds it necessary to
use different conditions, and allows development
for 48 h.
5 McIntire antigen was not demonstrable (but
not thoroughly investigated due to shortage of
material supplied).
6 "Ibrahim ag" is probably unique.
7 "Ikeda ag TS.1" appears to be CEA.
"Ikeda ag TS.2" is a distinct antigen, also
occurring in the samples submitted by Ibrahim
(ag 11) and Lamerz (ag 15).
8 Lamerz ag LCAA-1 was confirmed to be ferritin-
like.
LCAA-2 was confirmed to be lacto-
ferrin-like.
LCAA-3 was confirmed to be CEA-
like.
As such, these antigens occurred in several of
the other antigen samples (see Table IV).
Due to the polyspecific nature of ab 16, 17 and
18, it is difficult to draw conclusions as to which
ag samples contain antigens similar to those of
Lamerz.
9 "Gennings ag" is a distinct antigen occurring
also in Lamerz ag 19 (and possibly in ag 18).
10 "Nordquist ag" is a unique antigen ofhigh mol.
wt. Ford ab 3 reacts specifically with this
antigen.
to the appropriate antigen but also to
other proteins; these have been identified
where possible, and it is interesting that
in some instances these include the
"marker" investigated by another group.
In Table IV, the "identified" antigens
found to be components of the antigen
samples in each case are set out: Table VI
extends these results to incorporate more
data, and also indicates where antigens
were not demonstrable at all by these
techniques. This leads to the conclusion
that in these experiments 5 bronchial
tumour-associated reactions are evident,
which are distinct from already-known
markers and from normal human serum
proteins. By reference to Tables IV and VI
it can be concluded that the 5 distinct
antigens are as follows:
(1) "Wolf antigen WG": present in
Wolfag 2 only.
(2) "Ibrahim antigen": present in Ibra-
him ag 10.
(3) "Ikeda antigen TS.2": present in
Ikeda ag 12 and 13, Ibrahim ag 11
and Lamerz ag 15.
(4) "Gennings antigen": present in Gen-
nings ag 20 and Lamerz ag 18.
(5) "Nordquist antigen": present in
Nordquist ag 21.
DISCUSSION
Five distinct antigen-antibody reac-
tions derived from extracts of bronchial
tumours have been identified.
It was not possible in the experimental
conditions used in these studies to demon-
strate the activity of all of the antigens
and antisera. In some cases insufficient
material was available.
Where activity was demonstrated, it
was found that in some cases an antigen
studied by a participating group was also
present in the tumour extracts of other
groups, as indicated in Table IV. Despite
this there was no evidence that a single
antigen was the focus of study by more
than one group. The study illustrated also
the difficultiesofcomparingmanypartially
purified reagents. The presence of several
antigens in the preparations reflects to
some extent the limitation of absorbed
polyvalent antisera as tools for defining
unique antigenic determinants.
However, by identifying some of the
contaminating proteins with the aid of
fused-rocket IEP, and the use ofimmuno-
absorbent subtraction, further progress
can be made. For example, as a result of
identifying an anti-ac2-macroglobulin in
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antiserum 10 the development of an assay
for Wolf antigen A in human serum has
been facilitated (Wolf et al., 1981).
Whether any of the 5 distinct antigens
defined in these bronchial-carcinoma ex-
tracts will prove to be clinically useful, has
yet to be determined. Not one ofthem has
so far established a dominant claim for
wider attention.
The difficulties resulting from the use of
conventional antisera in defining tumour
markers serve to emphasize the attrac-
tions of monoclonal antibodies as tools in
this type ofwork.
This work was partly financed by the Medical
Research Council, U.K. and partly by Dako, Copen-
hagen, Denmark. Thanks are due to Miss Tove
Dannemann Jensen for her competent technical
help.
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